Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Go back to Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 175.77 +1.62 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $174.15 | 52 Week High | $58.46 | |||
| Open | $174.25 | 52 Week Low | $31.25 | |||
| Day High | $177.30 | P/E | N/A | |||
| Day Low | $173.43 | EPS | $-0.69 | |||
| Volume | 1,129,506 | |||||
